RRR-alpha-tocopherol Composition for Infant Visual Acuity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for improving visual processing and visual acuity in infants are inadequate, as they often use synthetic alpha-tocopherol, which contains equal amounts of stereoisomers, including less bioavailable forms, rather than the naturally preferred RRR-alpha-tocopherol, and lack effective means to selectively reduce non-RRR-alpha-tocopherol accumulation in the occipital cortex.
Innovation Solution
Administering a nutritional composition comprising RRR-alpha-tocopherol and carotenoids to infants, which preferentially increases RRR-alpha-tocopherol accumulation and reduces non-RRR-alpha-tocopherol in the occipital cortex, thereby enhancing visual processing and acuity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic alpha-tocopherol is administered to infants, then the visual processing and visual acuity may be improved, but the bioavailability is reduced due to equal amounts of less bioavailable stereoisomers
Solution Approach 1:
The patent changes the stereoisomeric composition parameter of alpha-tocopherol from synthetic (equal mixture of all 8 stereoisomers) to natural (RRR-alpha-tocopherol only). This parameter change ensures that only the most bioavailable form is administered, resolving the contradiction between improving visual processing and maintaining sufficient bioavailable substance quantity.
2Reliability
If synthetic alpha-tocopherol is administered to infants, then the visual processing and visual acuity may be improved, but the accumulation of non-RRR-alpha-tocopherol stereoisomers in the occipital cortex increases
Solution Approach 1:
The patent extracts and eliminates the harmful non-RRR-alpha-tocopherol stereoisomers from the administration composition. By using only natural RRR-alpha-tocopherol instead of synthetic mixtures, the patent removes the harmful component that causes unwanted accumulation in the occipital cortex while maintaining the beneficial visual processing effects.
3Quantity of substance
If natural RRR-alpha-tocopherol is administered to infants, then the bioavailability is maximized, but the visual processing improvement may be insufficient without carotenoid supplementation
Solution Approach 1:
The patent merges RRR-alpha-tocopherol with carotenoids in a single nutritional composition administered to infants. This combination approach ensures that both the most bioavailable form of Vitamin E and the visual-function-supporting carotenoids are provided together, maximizing both bioavailability and visual processing improvement reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively enhances the concentration of RRR-alpha-tocopherol in the occipital cortex, improving visual processing and acuity in infants by ensuring the most bioavailable form of Vitamin E is utilized, while reducing less active stereoisomers, thus supporting the development of visual functions.
Implementation Method 1
the brain also preferably selects and absorbs RRR-alpha-tocopherol as compared to the seven other stereoisomers
Implementation Method 2
the carotenoid reduces the accumulation of non-RRR-alpha-tocopherol in the occipital cortex of the infant
Data Source
AI summary
Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed. Methods for improving the development of the visual processing, visual acuity, or both, of an infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed.